125 related articles for article (PubMed ID: 35105169)
21. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
22. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
[No Abstract] [Full Text] [Related]
23. Model for predicting the burden and cost of treatment in cervical cancer and HPV-related diseases in Thailand.
Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Jirakorbchaipong P; Kitsiripornchai S; Taneepanichskul S
Eur J Gynaecol Oncol; 2012; 33(4):391-4. PubMed ID: 23091896
[TBL] [Abstract][Full Text] [Related]
24. Cost information of chemotherapy for cervical and endometrial cancer in Japan.
Kamijo Y; Ichikawa M
Jpn J Nurs Sci; 2014 Jul; 11(3):190-9. PubMed ID: 25065965
[TBL] [Abstract][Full Text] [Related]
25. Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Lam C; Diessner B; Andrade K; Stackland S; Park L; Mehta S; Lin F; Kwong WJ
J Comp Eff Res; 2024 Apr; 13(5):e230166. PubMed ID: 38647165
[No Abstract] [Full Text] [Related]
26. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Insinga RP; Ye X; Singhal PK; Carides GW
Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
[TBL] [Abstract][Full Text] [Related]
27. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
28. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
J Med Econ; 2021; 24(1):469-478. PubMed ID: 33784916
[TBL] [Abstract][Full Text] [Related]
30. Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
Dacosta Byfield SA; Adejoro O; Copher R; Chatterjee D; Joshi PR; Worden FP
Adv Ther; 2019 Apr; 36(4):896-915. PubMed ID: 30820872
[TBL] [Abstract][Full Text] [Related]
31. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.
Jewell EL; Kulasingam S; Myers ER; Alvarez Secord A; Havrilesky LJ
Gynecol Oncol; 2007 Dec; 107(3):532-40. PubMed ID: 17900674
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study.
Shao C; He J; Stein K; Keefe S
Curr Med Res Opin; 2020 Jul; 36(7):1187-1194. PubMed ID: 32314603
[No Abstract] [Full Text] [Related]
33. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
Burke TA; Wisniewski T; Ernst FR
Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
[TBL] [Abstract][Full Text] [Related]
34. Shortcomings and deficits in surgical treatment of gynecological cancers: a German problem only?
Münstedt K; von Georgi R; Zygmunt M; Misselwitz B; Stillger R; Künzel W
Gynecol Oncol; 2002 Sep; 86(3):337-43. PubMed ID: 12217757
[TBL] [Abstract][Full Text] [Related]
35. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
36. Phase-specific healthcare costs of cervical cancer: estimates from a population-based study.
Liu N; Mittmann N; Coyte PC; Hancock-Howard R; Seung SJ; Earle CC
Am J Obstet Gynecol; 2016 May; 214(5):615.e1-615.e11. PubMed ID: 26627729
[TBL] [Abstract][Full Text] [Related]
37. [Tumors of the cervix, endometrial tumors].
Vannieuwenhuyse G; Graesslin O
Rev Prat; 2015 Mar; 65(3):425-33. PubMed ID: 26016212
[No Abstract] [Full Text] [Related]
38. A cost comparison of two strategies for treating stage IB2 cervical cancer.
Lachance JA; Darus CJ; Stukenborg GJ; Schneider BF; Rice LW; Jazaeri AA
Int J Gynecol Cancer; 2008; 18(2):274-8. PubMed ID: 18334009
[TBL] [Abstract][Full Text] [Related]
39. Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments.
White ID; Sangha A; Lucas G; Wiseman T
Gynecol Oncol; 2016 Dec; 143(3):664-673. PubMed ID: 27671030
[TBL] [Abstract][Full Text] [Related]
40. Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).
Arians N; Foerster R; Rom J; Uhl M; Roeder F; Debus J; Lindel K
Radiat Oncol; 2016 Mar; 11():44. PubMed ID: 26988089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
